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A B S T R A C T
Intermediate filaments (IFs) play key roles in cell mechanics, signaling and homeostasis. Their assembly and
dynamics are finely regulated by posttranslational modifications. The type III IFs, vimentin, desmin, peripherin
and glial fibrillary acidic protein (GFAP), are targets for diverse modifications by oxidants and electrophiles, for
which their conserved cysteine residue emerges as a hot spot. Pathophysiological examples of these modifica-
tions include lipoxidation in cell senescence and rheumatoid arthritis, disulfide formation in cataracts and ni-
trosation in endothelial shear stress, although some oxidative modifications can also be detected under basal
conditions. We previously proposed that cysteine residues of vimentin and GFAP act as sensors for oxidative and
electrophilic stress, and as hinges influencing filament assembly. Accumulating evidence indicates that the
structurally diverse cysteine modifications, either per se or in combination with other posttranslational mod-
ifications, elicit specific functional outcomes inducing distinct assemblies or network rearrangements, including
filament stabilization, bundling or fragmentation. Cysteine-deficient mutants are protected from these altera-
tions but show compromised cellular performance in network assembly and expansion, organelle positioning and
aggresome formation, revealing the importance of this residue. Therefore, the high susceptibility to modification
of the conserved cysteine of type III IFs and its cornerstone position in filament architecture sustains their role in
redox sensing and integration of cellular responses. This has deep pathophysiological implications and supports
the potential of this residue as a drug target.
1. Introduction
Intermediate filaments (IFs) are cytoskeletal structures critical for
cell mechanics, which maintain a close interplay with the other cytos-
keletal systems, namely, actin microfilaments and microtubules [1,2].
IFs act as integrators of cytoskeletal responses and cell behavior. They
are constituted by homo- or heterooligomers of proteins, which are
classified into six different families depending on their structure. Ker-
atins (types I and II), vimentin (type III) and nuclear lamins (type V) are
examples of the different protein families and illustrate the critical roles
of IFs in epithelial biology, cytoplasmic and nuclear mechanics and
stress sensing, and nuclear support and function, respectively [3].
Mutations in many IF proteins lead to devastating diseases, ranging
from epidermolysis bullosa (keratin) [4] to premature aging syndromes
(lamins) [5], which highlight their key function in cell and organism
homeostasis.
The type III IF protein family comprises vimentin, glial fibrillary
acidic protein (GFAP), desmin and peripherin, which are important
components of the cytoplasmic cytoskeleton and are expressed in spe-
cific cell types. Vimentin is present mainly in cells of mesenchymal
origin and is the most widely expressed type III IF protein [6,7],
whereas the expression of desmin, GFAP and peripherin is mainly re-
stricted to the muscle and glial cells and neurons of the peripheral
system, respectively [6]. Vimentin is also the most thoroughly studied
member and is frequently considered as a prototype for the assembly,
regulation and implications of the constituents of this family [7].
Therefore, many of the features outlined below derive from research on
vimentin.
Type III IF proteins form a dynamic network that typically extends
from the periphery of the nucleus to the cell membrane, interacting
with and seemingly modulating the behavior of the actin and tubulin
cytoskeletons [7–10]. Vimentin influences many critical cellular pro-
cesses including cell plasticity and mechanics, deformability, cell cortex
properties in interphase and mitosis, migration and adhesion, cell di-
vision, organelle positioning, and nucleus and DNA integrity under
stress [6–8,11–13]. In turn, GFAP has been involved in astrocyte
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migration, integrity and signaling [14], whereas desmin is important
for striated muscle cell differentiation and survival, mitochondrial
function and mechanochemical signaling [6,15]. Therefore, these pro-
teins function in the maintenance of normal cell homeostasis and their
alterations are involved in pathology, including cancer aggressiveness
and invasion, heart disease and neurodegenerative disease in the case of
vimentin, desmin and GFAP, respectively [15–17].
1.1. Structural aspects of type III IFs
IF proteins share a three domain structure comprising a disordered
N-terminal head, a central α-helical rod domain and a disordered C-
terminal tail (Fig. 1). The rod domain is in turn divided into several α-
helical segments joined by linkers. Several excellent reviews have
covered the vast work performed on the structure and assembly of these
proteins [3,18]. Therefore, only a simplified view will be provided in
this review. Exhaustive in vitro work has outlined the process of fila-
ment formation. The disposition of hydrophobic residues of the rod
towards the same side of the α-helix favors monomer association into
parallel coiled-coil dimers. Then, dimers associate into staggered anti-
parallel tetramers, a process favored by electrostatic interactions due to
the periodical arrangement of positive and negative charge spots. Tet-
ramers then associate laterally to form short “cylinders”, known as
“unit-length filaments” (ULFs), typically constituted by eight tetramers.
These units connect end to end to form filaments. However, given the
staggered disposition of dimers in tetramers, considerable imbrication
of dimer extremities needs to occur during filament elongation. In fact,
superposition of N-and C-terminal ends of the rod domains of con-
secutive ULFs, involving an approximately 30-residue overlap, has been
proposed for vimentin [19].
The complete crystal structures of vimentin, or other type III IF
proteins, are not available yet. Nevertheless, integration of the in-
formation from a variety of structural techniques, together with mole-
cular modeling, have rendered an advanced view of the configuration
of tetrameric vimentin and have provided models for the disposition of
vimentin in filaments [18,20]. Importantly, early crosslinking experi-
ments already indicated that vimentin undergoes important re-
organization during filament assembly and elongation [21,22]. It is
accepted that, within filaments, different vimentin tetramer con-
formations coexist, depending on the relative positions of dimers, which
can adopt N-terminal or C-terminal overlaps or N-terminus-C-terminus
coupling, known as A11, A22 and ACN conformations, respectively
(Fig. 1). Recently, strategies like deuterium exchange, electron para-
magnetic resonance and molecular dynamics have provided further
insight into IF protein organization [20,23,24].
Type III IF proteins share a high degree of sequence identity, not
only among the members of the family but also between species.
Therefore, the positions of hydrophobic residues and clusters of charged
amino acids are highly conserved. Moreover, these proteins present
numerous target residues for phosphorylation, mainly in the head do-
main, which are very important for the regulation of filament assembly.
Remarkably, all members of this family possess a cysteine residue, lo-
cated at positions 328, 294, 333 and 324 (numbered from the initial
methionine) in the sequences of human vimentin, GFAP, desmin and
peripherin, respectively, which in the first three members is also the
only cysteine residue. Moreover, this residue is conserved in all species,
from zebra fish to humans. The conserved cysteine residue is located in
the last coil segment of the rod, facing outwards from the vimentin
dimer [25]. Notably, whereas in the A11 tetramer cysteine residues
from different dimers will be far apart, in the A22 tetramer con-
formation, the cysteine residues would be closer. Nevertheless, in-
formation on the three-dimensional organization of tetramers in the
body of the filament would be necessary in order to ascertain the re-
lative positions of cysteine residues from different tetramers. From the
existing models of vimentin [19,24], it could be hypothesized that the
cysteine residue would occupy a position close to the space needed for
the interdigitation of adjacent ULFs during elongation (Fig. 1). There-
fore, bulky modifications of this residue could lead to alterations in
assembly. In the context of oxidative modifications, other nucleophilic
residues prone to oxidation or adduction of electrophiles, including
several histidine, lysine and arginine residues, as well as the single
tryptophan (W290 in vimentin), are also conserved among members of
the type III IF family, as well as between species [26,27].
1.2. Posttranslational modifications of type III IFs
In cells, type III IFs are under constant remodeling through the ex-
change between the assembled polymers and the pool of soluble sub-
units, and their dynamics is tightly controlled by posttranslational
modifications (PTMs), mainly phosphorylation [28]. Regulation of vi-
mentin by phosphorylation is critical in mitosis, where the spatio-
temporally concerted action of several kinases allows its reorganization,
which is important for completion of cytokinesis [29]. In addition, the
extent of phosphorylation together with protein-protein interactions
influences whether vimentin is disassembled in mitosis or remains in
filaments [30] that intertwine with and modulate the actin cortex, al-
lowing proper mitosis progression [8].
Type III IFs can suffer diverse enzymatic PTMs, including ubiquiti-
nation and sumoylation [31], glycosylation [32], proteolysis [33], and
acetylation [34]. One important modification with significant patho-
physiological consequences is citrullination [35]. Citrullinated vi-
mentin is an autoantigen involved in the pathogenesis of rheumatoid
arthritis and in antitumor immunity [36,37]. In turn, citrullinated
GFAP has been detected in several diseases, including Alzheimer's dis-
ease (AD) and multiple sclerosis, and it has been reported to constitute
an early response to retinal injury [38,39]. Enzymatic PTMs of type III
IF proteins have been considered in several important reviews [31,40].
Nevertheless, type III IFs are also subjected to numerous non-enzymatic
modifications, including those induced by oxidants and electrophiles,
which are arising as important determinants in filament structure and
function and will be considered in more detail below.
1.3. General aspects of PTMs frequently associated with oxidative stress
All cells are exposed to reactive oxygen and/or nitrogen species
(ROS/RNS) and possess defense mechanisms to avoid excessive oxida-
tion. Oxidative stress arises when oxidant levels, either from en-
dogenous or exogenous sources, surpass the cellular antioxidant de-
fenses. Protein oxidation can occur upon exposure to diverse oxidant
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recent reviews have addressed the oxidative modifications of proteins
[41,42], and of cysteine residues in particular [43,44], and provided
detailed methodological information for their assessment. In addition,
oxidative stress can increase the production of electrophilic species
eliciting additional PTMs.
Depending on their type and/or extent, oxidative and electrophile-
induced PTMs can contribute to cell homeostasis, signaling or stimu-
lation of antioxidant defenses, or result in protein dysfunction,
(caption on next page)
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misfolding or aggregation, and to the impairment of protein interac-
tions and functions, in the cell or in the extracellular medium [45–47].
Importantly, these PTMs can lead to structure-specific outcomes. Thus,
depending on the protein, certain modifications can have virtually no
consequences on protein function, whereas others can lead to activation
or inhibition, or to the modulation of protein-protein interactions or
subcellular localization [45,48,49].
Cysteines are the most nucleophilic residues and readily attack and
form adducts with electrophiles of very diverse structure. Therefore, the
moieties bound to a protein through cysteine residues can be very
varied, and range from the addition of one oxygen atom or one oxygen
plus one nitrogen atom, in the case of sulfenylation (sometimes called
sulfenation) and nitrosation (frequently referred to as nitrosylation)
[50], respectively, to bulky substitutions by endogenous reactive spe-
cies or drugs (Fig. 2). Formation of disulfide bonds can result in cova-
lent binding of the protein to small molecules, like cysteine or glu-
tathione (GSH) (cysteinylation and glutathionylation, respectively), or
to other proteins. Importantly, cysteine modifications can sometimes
interconvert. Disulfide exchanges between proteins and small mole-
cules can occur. Moreover, the nitroso moiety can be transferred be-
tween proteins or lead to NO release. Interestingly, nitrosoglutathione
(GSNO) can induce transnitrosation or glutathionylation of target cy-
steine residues depending on their nucleophilicity. Thus, highly nu-
cleophilic thiols break the S–NO bond leading to glutathionylation,
whereas moderately nucleophilic thiols are more likely to become
transnitrosated [51]. In turn, oxidized and electrophile adducted moi-
eties can suffer further transformations leading to derived species and/
or protein crosslinks [41].
An important aspect of cysteine oxidative modifications is stability.
While some modifications are readily reversible (e.g. sulfenylation,
disulfide formation and nitrosation), others are considered irreversible
due to their high stability under biological conditions (e.g. sulfonyla-
tion). Some reversible modifications of cysteine residues, including
glutathionylation or nitrosation have been considered as protective
mechanisms preventing the occurrence of “irreversible” modifications,
thus preserving protein function [52]. Cysteine residues can also un-
dergo a plethora of enzymatic PTMs, including some catalyzed oxida-
tive modifications, acylations, prenylation and methylation (for C-
terminal isoprenylated cysteine residues), etc. [53–55]. Therefore, in
certain cases there can be interplay between these PTMs leading to
structurally and functionally diverse proteoforms [49].
The term lipoxidation refers to the modification of proteins by
reactive products of lipid peroxidation [56]. These electrophilic lipids
are generated under physiological conditions at moderate levels and
they participate in signaling pathways and adaptive and cytoprotective
responses that have been recently reviewed [57]. However, under pa-
thological situations commonly associated with oxidative stress, the
levels of these agents increase, favoring their reaction with other bio-
molecules including other lipids, DNA and proteins. The structures and
concentrations of electrophilic lipids can be very varied (Fig. 3), and
can range from small aldehydes, like acrolein or malondialdehyde
(MDA) (56 and 72 Da, respectively), to cyclopentenone prostaglandins
(cyPG) or isoprostanes (300–400 Da), or even oxidized or nitrated
phospholipids (700–900 Da). Indeed, the number of reactive lipid
species expands to several hundred [56]. Adducts with protein residues
occur mainly through Schiff base formation with amino groups or
Fig. 1. Schematic features of type III intermediate filament proteins and cartoon view of their assembly. The length of the full protein and of the head, rod and
tail domains is shown for the four members of the type III class of IF (upper panel). Dots indicate the position of the conserved cysteine residue (black) and that of the
additional cysteine of peripherin (red). Amino acid numbering for the various domains corresponds to the following entries from Uniprot: vimentin, P08670; GFAPα,
P14136; desmin, P17661; peripherin, P41219. The lower panel depicts a cartoon view interpretation of the assembly process of type III IFs, as inferred from
numerous in vitro works (see the text for details). Please note that in unit length filaments (ULFs), individual tetramers are deliberately not perfectly aligned. The 2-
ULF “filament” shown at the bottom illustrates the potentially critical position of the cysteine residue, which could lie close to the region required for the “plugging”
of two ULFs. Modifications of this residue with bulky moieties may have important consequences for filament assembly or elongation. Although the A11 tetramer
assembly is considered the starting unit, once assembled in filaments, vimentin dimers can fall in different relative positions, giving rise to several tetrameric
configurations, including those outlined in the figure by color shadowing: A11 tetramer (blue), ACN tetramer (yellow) and A22 tetramer (green). These tetrameric
configurations have been schematically extracted at the right for easier visualization. Depictions of IF monomer and ULF are modified from Ref. [13]. (For inter-
pretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Fig. 2. Schematic representation of several mod-
ifications of vimentin C328. The figure shows a
cartoon of a stretch of the alpha helical structure of a
segment of vimentin and the C328 lateral chain
prepared using PyMol and data from the PDB entry
3KLT [202]. Structures of nitrosocysteine, acrolein
and 15d-PGJ2 have been obtained from Pubmed
Compound. This schematic representation illustrates
the diverse size of the moieties that can bind to C328,
potentially imposing steric hindrances or altering
interactions required for filament assembly.
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through Michael addition with various residues bearing nucleophilic
moieties, like the thiol group of cysteine, imidazole of histidine and
amino of lysine residues [48]. The stability of adducts formed will be
influenced by several factors including the nature of the adducted re-
sidue and the occurrence of additional intramolecular reactions [58].
Moreover, both, non-enzymatic and enzymatic reversal of certain
electrophilic lipid-protein adducts has been reported in vitro as well as
in cellular models [59–61]. Therefore, lipoxidation can constitute a
dynamic modification contributing to signaling mechanisms [60,61].
Given the structural variety of adducts their functional consequences
(structure-activity relationships) can be diverse. There are several
examples of differential effects of lipoxidation of cysteine residues,
depending on the adducted moiety. Adduction of distinct electrophilic
lipids to Ras proteins can differentially influence activation and sub-
cellular localization [49,62]. Similarly, the aldo-keto reductase enzyme
AKR1B1 is activated by addition of small moieties but inhibited by
larger ones [63].
CyPG are electrophilic eicosanoids derived from prostaglandins by
non-enzymatic dehydration [64]. They are characterized by the pre-
sence of an α,β-unsaturated carbonyl group in the cyclopentane ring
that allows Michael adduct formation, preferentially with cysteine re-
sidues. One example of these eicosanoids is 15-deoxy-Δ12,14-
Fig. 3. Structures of diverse electrophilic species involved in lipoxidation and examples of cytoskeletal type III IF rearrangements. Upper panel, the
structures of malondialdehyde (MDA), 4-hydroynonenal (HNE), prostaglandin A1 (PGA1), and nitrated 1-palmitoyl-2-oleyl-phosphatidyl choline (NO2-POPC), are
shown. Lower panel, confocal fluorescence microscopy images of IF reorganization in response to several strategies aimed at inducing cysteine modification in cells.
A normal vimentin network together with examples of previously reported functional outcomes, observed upon treatment of cells with various electrophilic agents,
are shown. Aggresome formation is illustrated by HNE treatment, as in Ref. [13]; network fragmentation alone or accompanied by solubilization, characterized by
the diffuse background, correspond to treatment with diamide or diamide plus calyculin A, respectively, as in Ref. [91]; filament bundling is exemplified by treatment
with 15d-PGJ2 as in Ref. [91], and peripheral condensation, by treatment with NO2-POPC as in Ref. [115]. Scale bar, 20 μm. Please note that the effects observed in
cells can be the consequence of direct and/or indirect modifications of IF proteins, as well as of PTM interplay.
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prostaglandin J2 (15d-PGJ2) (Fig. 2), which has been broadly studied
both in cell culture systems and in vivo. The effects of cyPG, as those of
many lipoxidation agents and oxidants, can have a dual or hormetic
nature, depending on time or concentration. Low concentrations can
activate the cellular antioxidant defenses and potentiate the initial in-
flammatory response, whereas high levels can elicit anti-inflammatory
and antiproliferative effects and induce cytotoxicity [65,66]. In-
tracellular GSH is an important determinant of cyPG distribution and
effects through various mechanisms, including the formation of cyPG-
GSH adducts that can be involved in cyPG transport or sequestering,
leading to a differential modification of proteins depending on the
subcellular compartment [49].
Numerous studies on protein oxidative damage use the term car-
bonylation to refer to the formation of carbonyl groups on proteins.
Chemically, carbonylation refers to the addition of carbon monoxide to
a compound leading to the appearance of a carbonyl group. Appearance
of carbonyl groups on proteins can occur by several mechanisms, in-
cluding oxidation of amino acid lateral chains, oxidative deamination
or formation of certain adducts with compounds that retain a free
carbonyl group, as in some types of lipoxidation, like Michael addition
of cyPG or of HNE, or after glycation or glycoxidation. As none of these
processes involves carbon monoxide addition the term “formation of
protein carbonyls”, should be preferred instead of protein carbonyla-
tion, which, as stated above is not selective for a particular type of
modification, but can arise by multiple mechanisms, as detailed in Ref.
[67].
2. Vimentin
Early functional studies in cells lacking vimentin showed altered
nuclear morphology and impaired distribution of certain organelles
[68]. However, the finding that vimentin knockout mice were fertile
and apparently developed normally [69] dimmed the interest in this
protein. Nevertheless, subsequent works have established the role of
vimentin as a key player in cellular organization and as a modulator
and effector of numerous biological and pathophysiological processes.
Indeed, vimentin knockout animals do not respond normally to many
kinds of stress and show alterations in immune function [70], autop-
hagy, cell migration and division, wound healing, function of the cen-
tral nervous system, and arterial remodeling [71], among others. In
addition, vimentin is an important marker and player of epithelial
mesenchymal transition and its expression in certain types of cancer
can be considered a sign of malignancy and invasiveness [16]. It is also
necessary for cellular entry and/or toxic cellular actions of diverse
bacterial and viral pathogens [72–74]. In contrast to other IF proteins,
only a few mutations in the vimentin sequence have been identified.
The E151K mutation [75], the heterozygous frameshift from V6C [76]
and the missense (Q208R) [77] mutation have been associated with
Fig. 4. Schematic illustration of the potential effects of oxidative modifications on type III intermediate filament assembly. A hypothetical model to
conciliate the differential effects of certain oxidants on the assembly of soluble IF proteins and preformed filaments is shown. A very simplified representation of IF
dimers (rectangles) and IF tetramers is depicted, showing the approximate positions of the cysteine residues (black dots). On the left, disulfide formation (red ellipses)
or modification of cysteine residues by bulky moieties (yellow shapes) in soluble IF tetramers may interfere with their subsequent assembly in ULFs or with ULF
elongation upon induction of polymerization, or may impede conformational rearrangements needed for proper assembly. Conversely, on the right, preformed
filaments could undergo a certain degree of modification on accessible residues, or of disulfide formation between close cysteine residues, without suffering sub-
stantial disruption of their assembly. Nevertheless, modification above a certain threshold could lead to filament disruption. (For interpretation of the references to
color in this figure legend, the reader is referred to the Web version of this article.)
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cataract development. Recently, a dominant vimentin variant (L387P)
causing a rare syndrome with premature aging has been reported [78].
Vimentin is the target of numerous enzymatic and non-enzymatic
PTMs, some of which have been outlined above. Accumulating evi-
dence indicates that vimentin behaves as a sensor for several kinds of
stress, including oxidative stress and generation of lipid- or sugar-de-
rived electrophiles that target several residues leading to versatile
network remodeling [56,79] (Fig. 3). The single cysteine residue of
vimentin (C328) appears to be highly susceptible to oxidation or ad-
dition of diverse species, both in vitro and in cells [25,80–84], sug-
gesting that it is a preferred site of modification. Moreover, modifica-
tions of C328 play a key role in redox-related reorganizations of
vimentin filaments, with diverse consequences on cell behavior.
Disulfide formation and other cysteine oxidations. Early studies
using cytoskeleton preparations from several cell types subjected to
oxidative in vitro crosslinking with Cu2+-phenanthroline showed the
formation of homo- and heterodimers of either vimentin and desmin or
vimentin and GFAP, which led to propose that both proteins were
present in hybrid filaments [85,86]. These studies indicated that cy-
steine residues in the “crosslinkable” units were exposed to the protein
surface at a distance sufficiently close to allow interaction. Oxidized
oligomeric species of vimentin were also detected in fibers isolated
from eye lenses of several species, when extracted in the absence of
beta-mercaptoethanol [87]. Later studies putatively identified vimentin
as one of the proteins undergoing disulfide bonding in fibroblast-like
synoviocytes subjected to oxidative stress by treatment with H2O2 [88],
and soon after, Traub et al., showed that oxidized vimentin and desmin
species, including homo- and heterooligomers of both proteins, formed
abnormal filaments, which could be restored by reducing agents [89].
The involvement of the cysteine residue in disulfide formation and
its impact on assembly was confirmed by using a C328A vimentin
mutant that showed resistance to crosslinking by oxidation with H2O2
and CuCl2 and formed apparently normal filaments in vitro [25]. It was
then postulated that crosslinking of vimentin wild type could occur
between neighboring dimers arranged in the A22 conformation, in
which the cysteine residues fall in a closer position (Fig. 1). However, it
was noted that this arrangement was still not ideal for disulfide bond
formation unless additional flexibility or molecular motion within the
tetramer occurred to allow a closer contact between the cysteine lateral
chains [25].
Dimeric species of vimentin have also been observed in SDS-PAGE
gels upon treatment with bifunctional cysteine crosslinkers, like di-
bromobimane (spacer arm 4.66 Å), both in vitro and in cells [13], in-
dicating that in intact cells cysteine residues within filaments can also
be present at a close distance. Moreover, the use of this reagent allowed
obtaining vimentin-GFAP heterodimers from intact astrocytoma cells
[90], thus suggesting the presence of both proteins in the same fila-
ments as proposed in earlier in vitro works [85,86].
Recently, the electrophilic reagent diamide has been used to induce
vimentin disulfide bonding [91]. This reagent reacts sequentially with
two thiol groups facilitating disulfide bond formation. Diamide-treated
purified vimentin appears as monomer and dimer species in non-re-
ducing SDS-PAGE gels in approximately a 1:1 proportion. Notably,
disulfide formation profoundly impaired subsequent polymerization
into filaments of vimentin wild type, but not of a cysteine-deficient
mutant. However, preformed filaments underwent disulfide formation
to a similar extent than the soluble protein but were not disrupted by
short diamide treatments. Therefore, these results suggest that pro-
moting disulfide bond formation in soluble tetramers may lead to their
association in conformations that are not productive for subsequent
assembly, whereas once filaments are formed and the subunits are in
place, a certain number of disulfide bonds can form between cysteines
that fall within close distance without disrupting the whole filament
(Fig. 4). Remarkably, although resistant to oxidation by diamide, fila-
ments formed in vitro by a C328S mutant showed subtle, but sig-
nificant, differences with vimentin wild type, calling attention on the
importance of this residue for filament assembly [91,92]. Interestingly,
diamide induces a major disruption of vimentin filaments in cells in
such a way that filaments rapidly reorganize into discrete dots [13,91].
In cells, both soluble and polymerized vimentin coexist and exchange.
Therefore, oxidation of soluble vimentin could hamper its incorporation
into filaments leading to network disruption. Moreover occurrence of
additional PTMs as a consequence of oxidative stress, could also con-
tribute to diamide-induced filament fragmentation. Nevertheless, the
fact that the C328S vimentin mutant is completely resistant to this ef-
fect, confirms the critical role of the modification of the cysteine residue
in vimentin reorganization [91].
Formation of mixed disulfides can also occur between vimentin and
small thiol-containing molecules, like GSH (glutathionylation) or cy-
steine (cysteinylation). Vimentin glutathionylation has been observed
in several experimental models. Stimulation of isolated aortic rings with
acetylcholine led to vimentin glutathionylation through an eNOS-de-
pendent mechanism [93]. Notably, in this model system, glutathiony-
lation can occur directly or after denitrosation. As eNOS possesses basal
activity in endothelial cells, these observations suggest that glutathio-
nylation could occur under basal conditions and constitute a physio-
logical regulatory mechanism. Indeed, vimentin glutathionylation has
been detected in control mouse embryonic fibroblasts [94]. Never-
theless, this modification increases under conditions of oxidative stress.
In particular, loss of function of the KRIT1 gene, which is associated
with the pathogenesis of cerebral cavernous malformations, induces a
decrease in the GSH/GSSG ratio and increased glutathionylation of
several proteins, including vimentin, in cellular models of the disease
[94]. Glutathionylation of vimentin has also been observed in oxida-
tively stressed T-lymphocytes or COS7 cells exposed to NO donors
[93,95], and in human senescent fibroblasts, where it has been con-
nected with cell growth arrest and cell death [96]. Moreover, data
mining of the oxidized thiol proteome, has found a high proportion of
vimentin C328 involved in disulfide bonding in aging and cataractous
lenses [82]. From the functional perspective, the vimentin cysteine
residue has been compared to cryptic cysteines in other proteins, in
which glutathionylation could contribute to protein elasticity [97]. In
addition, recent studies indicate that quantitative vimentin glutathio-
nylation impairs vimentin elongation and provokes pre-formed filament
severing [98], supporting the view that modification of C328 with
bulky moieties could have important consequences for filament as-
sembly. Nevertheless, the functional implications of vimentin glu-
tathionylation in cells have not been fully elucidated and could depend
on the proportion of the protein modified, and/or represent a protective
mechanism against irreversible modifications.
The oxidation of vimentin in the extracellular space deserves special
attention. Vimentin can be exposed at the cell surface or secreted by
several cell types [99,100]. Cell surface vimentin can be labeled by cell-
impermeable cysteine reagents. The observation that labeling can be
increased by pretreatment with the reducing agent N-acetyl-cysteine
suggests that part of the protein exposed is reversibly oxidized [101].
Interestingly, oxidative stress increases extracellular exposure of vi-
mentin, frequently in an oxidized form [100], and it has been proposed
that this phenomenon could constitute an early response of cells to
oxidants from the extracellular space, and at the same time, generate
oxidized and secreted species of vimentin that could be involved in
pathogenesis of autoimmune diseases or act as a vehicle amplifying
oxidative stress and lipid oxidation [74,102].
Nitrosation. The above observations show that vimentin cysteine
can be modified under (patho)physiological conditions. Shear flow is a
physiological stimulus that activates eNOS in endothelial cells leading
to increased NO levels that can induce protein S-nitrosation. Indeed,
vimentin was identified among the S-nitrosated proteins detected in
endothelial cells after treatment with an exogenous NO donor or upon
stimulation of endogenous NO production [103]. Moreover, C328 has
been identified as the nitrosated residue in endothelial cells after shear
stress, depending on eNOS activity [104], and after NO-donor exposure
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[105]. Vimentin nitrosation can also occur under basal conditions and
increase as a consequence of drug treatment. Statins, drugs widely used
to control cholesterol levels, modulate eNOS expression in endothelial
cells [106], and lead to increased eNOS activity and nitrosation of en-
dothelial proteins, including vimentin [107]. Nitrosation has been
proposed to occur in hydrophobic environments, and indeed, hydro-
phobicity plots predict C328 to be located in a hydrophobic motif,
QSLTCEVDA [104]. Interestingly, the sequence -[I/L]-X-C-X2-[D/E]-,
has been reported to constitute a consensus motif for iNOS-S100 cata-
lyzed transnitrosation [108], that can take place for instance in acti-
vated peripheral blood monocytes. Vimentin C328 is located in one
such motif and has been validated as a target for nitrosation through
this mechanism. The functional significance of vimentin nitrosation is
not fully understood, although in endothelial cells it has been proposed
to contribute to endothelial remodeling under flow. A recent study in-
dicates that S-nitrosation of vimentin at C328 does not hinder, but
slows down, vimentin elongation in vitro. These results shed light on
the different functional outcomes of structurally different C328 mod-
ifications [98]. In addition, being a readily reversible modification, S-
nitrosation could also act as a defense mechanism protecting proteins
from deleterious oxidative modifications.
Lipoxidation. The stability of some adducts formed between vi-
mentin and electrophilic lipids has allowed obtaining structural and
functional information on the role of the lipoxidation of vimentin cy-
steine, both in vitro and in cells. Modification of vimentin by cyPG in
vitro occurs selectively at C328 [80,91], and disrupts subsequent NaCl-
elicited polymerization, inducing filament widening and bundling and
formation of aggregates, in wild type but not C328S vimentin. Notably,
these differential effects occurred in conditions under which the extent
of vimentin lipoxidation was estimated to be approximately 10% [80],
which is in the range of that estimated after treatment of cells with
biotinylated cyPG analogs [109]. Nevertheless, at high 15d-PGJ2 con-
centrations this selectivity is lost, since these compounds can form
adducts with other nucleophilic residues, namely, histidine. Interest-
ingly, as observed with oxidants, preformed filaments appear to be
protected from disruption in vitro, even when modified to the same
extent, potentially due to a different topology of the modification
(Fig. 4).
The amenability of cyPG to labeling with biotin or other moieties
has allowed their use as probes for lipoxidation. Using biotinylated 15d-
PGJ2 or PGA1, vimentin was first identified as one of the major targets
for these eicosanoids in mesangial cells, in which they induce a marked
cytoskeletal rearrangement leading to perinuclear condensation of vi-
mentin filaments into thick bundles [109]. Besides filament condensa-
tion, cyPG provoke the dislodgement of vimentin from the actin cell
cortex in mitosis, which could have deleterious consequences for cell
division [8]. The use of a vimentin C238S mutant has allowed identi-
fying the cysteine residue as the key site for adduct formation and/or
for the induction of vimentin filament disruption by cyPG in several cell
types [13,80]. As other electrophilic lipids, cyPG covalently bind to
multiple cellular targets and induce oxidative stress on their own, thus
the possibility exists that some of their effects on the vimentin network
may be indirect. Indeed, in addition to lipoxidation, 15d-PGJ2 has been
shown to induce reversible cysteine oxidation (cysteinylation) of cer-
tain proteins [110]. Nevertheless, the fact that the effects of cyPG are
attenuated in the C328S mutant, both in vitro and in cells, indicate that
this residue is a critical site for the action of these eicosanoids.
HNE is one of the most studied electrophilic lipids. The levels of
HNE, and of HNE-protein adducts, increase under many pathophysio-
logical conditions, including inflammatory, neurodegenerative diseases
and aging [56,111], in some of which HNE can reach micromolar
concentrations [112]. Lipoxidation of vimentin by HNE has been de-
tected in human monocytic THP1 cells treated with this lipid by means
of immunological and derivatization methods, and C328 was identified
as the modification site using LC-MS/MS [81]. HNE-vimentin adducts
have also been identified in senescent fibroblasts, mainly in soluble
vimentin and vimentin fragments [113]. Notably, HNE can form several
types of adducts with proteins, both through Michael addition and
Schiff base formation [114]. In addition, HNE adducts can give rise to
protein crosslinks. Consistent with this broad reactivity, HNE can
modify both vimentin wild type and C328S in vitro [91]. However, the
functional consequences of the modification are different; whereas
HNE-pretreated vimentin wild type formed thicker and shorter fila-
ments with a tendency to laterally associate, C328S vimentin was
protected from these effects [91]. These results suggest that even
though HNE can bind to other residues, the modification of C328 is
functionally the most important. This is also supported by observations
in cells showing that HNE treatment induces a juxtanuclear accumu-
lation of vimentin wild type in thick bundles or aggregates, whereas in
cells expressing vimentin C328S, the network is preserved and filament
retraction is attenuated [13,56].
Among other lipoxidation agents, vimentin can be modified by
MDA. Interestingly, immunization of mice with senescent cells led to
the isolation of a polyreactive antibody that recognized vimentin at the
surface of senescent primary human fibroblasts. In addition, an increase
in vimentin modified by MDA at C328 was observed at the cell surface
of senescent cells and in plasma of aged senescence-accelerated mice
[83]. Based on these findings it was proposed that MDA-modified vi-
mentin could serve as a senescence marker and potentially be re-
cognized by the innate immune system to eliminate senescent cells.
Other electrophilic lipids potentially interacting with vimentin include
nitrated phospholipids (Fig. 3), which alter the cellular vimentin net-
work in a manner dependent on the presence of C328, and shield this
residue from alkylation in vitro [115].
Importantly, although the C328S mutant is protected from oxidative
insults in cells, it shows a lower efficiency than the wild type at forming
extended networks, supporting aggresome formation and promoting
organelle position [13]. Therefore, even conservative substitutions of
the cysteine residue have a measurable impact on vimentin function.
In spite of the importance of C328 in vimentin lipoxidation, mod-
ification of K235, but not of C328, by nonealdehyde has been detected
in hepatic tissue from patients with end stage alcoholic liver disease or
non-alcoholic steatohepatitis [116]. This modification eliminates the
positive charge of K235, disrupting its electrostatic interaction with
E230 [117]. This brings about the potential of lipoxidation to alter
protein-protein interactions, with consequences for cell activation and/
or cytotoxicity. Indeed, lipoxidized proteins are ligands for the receptor
for advanced glycated end products (RAGE), which has been involved
in the pathogenic consequences of hyperglycemia or inflammation. By
abolishing the positive charges of lysine residues, lipoxidation disrupts
the ion pairs with negative residues in their vicinity, enabling the latter
to interact with positive residues in RAGE, favoring the activation of
this receptor [118]. Through this mechanism, lipoxidized proteins
could contribute to propagate the damage.
Protein carbonyl formation (PCF). Formation of protein carbonyls
on vimentin has been reported in numerous studies using derivatization
approaches, although, in many instances, the sites of modification have
not been identified. Among evidence from cellular models, PCF on vi-
mentin has been detected in rat aortic smooth muscle cells treated with
homocysteine or bone morphogenic protein-4 (BMP-4) [119,120],
HUVEC treated with sodium arsenite [121], and lung epithelial cancer
cells exposed to acrolein or smoke extracts [122,123], these latter cells
showing also vimentin crosslinked products [122]. Vimentin bearing
protein carbonyls has been identified in non-tumor lung specimens of
patients with lung cancer with or without chronic obstructive pul-
monary disease [124]. Increased vimentin PCF has also been detected
in cultured fibroblasts from AD patients with respect to those of control
subjects, after exposure to Aβ(25–35). These observations suggest a
dysfunction of antioxidant responses in AD [125], and raise the im-
portance of vimentin as a target for oxidation in CNS diseases [126],
together with GFAP, as it will be detailed below. PCF can occur also as a
consequence of glycation. In primary cultured human dermal
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fibroblasts vimentin was glycated predominantly at lysine residues lo-
cated in linker regions likely exposed to the cytosol. This caused vi-
mentin redistribution into perinuclear aggregates, which was accom-
panied by loss of fibroblast contractile capacity. Glycated aggregated
vimentin was also detected in facial skin biopsies. Therefore, the ac-
cumulation of life-long vimentin glycation was proposed to contribute
to loss of skin contractile properties during aging [79].
Other modifications. Vimentin tyrosine nitration has been de-
tected by immunoprecipitation with an anti-3-nitrotyrosine antibody in
mitochondrial diseases [127]. A similar approach was used to identify
tyrosine nitrated vimentin in lung cancer [128]. However, in these
studies, identification of the nitration sites was not achieved.
Tryptamine-4,5-dione is a product of the oxidation of serotonin that
is highly reactive with thiols. Vimentin has been identified as a target
for this putative neurotoxin in SH-SY5Y neuroblastoma cells, suggesting
the modification of the thiol group, although this was not confirmed
[129].
In summary, a plethora of vimentin modifications has been identi-
fied to date in many pathophysiological situations. Oxidative and non-
oxidative modifications can coexist in many instances allowing their
interplay, but an understanding of their structural and functional con-
sequences requires further investigation.
3. GFAP
GFAP is the main IF expressed in mature astrocytes, which also
express vimentin [130,131]. GFAP can be expressed in other cell types
outside the nervous system, including fibroblasts and hepatic stellate
cells [80,132]. A particular feature of GFAP among type III IF proteins
is the existence of multiple isoforms that arise by alternative splicing
and differ mainly in the tail domain, some of which are not able to form
filaments on their own [14]. Here, we will focus on the most abundant
isoform that is GFAPα (Fig. 1). This protein plays complex functions in
astrocyte homeostasis which, to date, have not been totally unraveled.
Studies in knockout animals have yielded diverse results pointing to the
complexity of GFAP functions and their dependence on the experi-
mental system. Roles in astrocyte migration, organelle distribution and
mitosis have been defined. The presence of GFAP also influences neu-
ronal functions, axonal and neuronal regeneration and several aspects
of neurotransmission [14]. GFAP plays an important role in the re-
sponse to damage, including inflammation, physical or ischemic
trauma. In these processes, astrocytes become activated, overexpress
GFAP and resume the expression of other IFs, like nestin and synemin
[130]. GFAP appears to play a dual role in trauma, favoring the for-
mation of a glial scar that limits the damage at the early stages, but
slowing down regeneration at later stages [133]. The importance of
GFAP in brain homeostasis is highlighted by the devastating con-
sequences of its mutations, which lead to Alexander disease (AxD), a
rare neurodegenerative disease that causes leukodystrophy, epilepsy,
loss of brain white matter and ultimately death [17]. In AxD, GFAP
forms aggregates known as Rosenthal fibers that accumulate other
proteins as well, and show oxidative damage [134]. Interestingly, AxD
associated mutations often involve substitutions of the wild type re-
sidues by cysteines [135], which raises the possibility that they undergo
additional oxidative modifications.
GFAP is also a hub for PTMs and it has been reported to undergo
phosphorylation at multiple residues. Phosphorylation plays an im-
portant role in the regulation of filament assembly and in the pro-
gression of mitosis and cytokinesis [136,137]. Moreover, increased
phosphorylation of certain residues, in particular S13, has been asso-
ciated with pathological conditions including frontotemporal lobar
degeneration, AxD and hypoxia [138–140]. Other PTMs have also been
associated with disease, including glycosylation and citrullination, the
latter, rendering GFAP an autoantigen for autoimmune disease or ap-
pearing in conditions such as AD or ischemia reperfusion injury
[38,39]. Moreover, GFAP degradation products have been observed in
neurodegenerative diseases [141] as well as in models of viral infection
[33].
GFAP can be targeted by numerous oxidative modifications and
appears frequently in proteomic studies of pathophysiological condi-
tions. Nevertheless, most studies focus on the variations of its levels as a
marker of nervous system injury and less attention has been paid to its
role as a target of damage. As specified above, disulfide formation
between GFAP monomers, likely belonging to different tetramers, has
been observed in vitro upon oxidative crosslinking [86]. Moreover,
bifunctional cysteine reagents also lead to homo- and heterodimers of
GFAP and vimentin in vitro and in cells [90]. These studies have sub-
stantiated the complex nature of these filaments in astrocytes and in
astrocyte models. Moreover, results from cellular models have shown
the requirement for the presence of the cysteine residue in GFAP for
proper filament assembly, which highlights the functional importance
of this residue. Interestingly, in primary astrocytes from mice deficient
in both GFAP and vimentin, the requirement for the cysteine residue
was more marked for GFAP than for vimentin, and this latter protein
seemed to rescue the defect in C294S GFAP assembly to some extent
[90]. GFAP has been found both in reduced and in reversibly oxidized
forms in brain tissue from a subject with mild AD, by employing a
differential thiol labeling protocol followed by 2D electrophoresis and
MS identification [142]. Finally, the appearance of high molecular
weight oligomers containing GFAP has been noted in several models of
disease, including AxD [143], although the nature of these oligomers
has not been characterized.
GFAP appears S-nitrosated in several conditions. A marked in-
crease in GFAP nitrosation has been observed in synaptosomes of
transgenic mice overexpressing mutated human amyloid precursor
protein compared to wild type, suggesting its involvement in pathology
[144]. However, S-nitrosation of GFAP has also been detected under
control conditions and found not to increase in experimental models of
murine autoimmune encephalomyelitis [145]. Therefore, the role of
this modification in pathogenesis or as a defense mechanism requires
further investigation.
Lipoxidation. Evidence on GFAP lipoxidation is gathering in recent
years. Pick's disease is a type of fronto-temporal dementia characterized
by severe atrophy of frontal and temporal lobes, neuronal loss and as-
trogliosis [146]. GFAP has been shown to be a major target of lipox-
idation by HNE and glycoxidative damage in brain samples from Pick's
disease patients compared to control subjects [146]. Down's syndrome
patients develop symptoms of premature aging, including neuro-
pathological features of AD. Therefore, observations in this syndrome
have been considered clues for the understanding of AD. A 3.3-fold
increase in HNE-modified GFAP has been observed in brain tissue from
Down's syndrome patients compared to controls by means of im-
munological detection with an anti-HNE antibody [147]. HNE also
targets elements of the protein degradation machinery and quality
control, the impairment of which could contribute to accumulation of
damaged or misfolded proteins. GFAP has also been recognized as a
major target for HNE-protein adduct formation in frontotemporal lobar
degeneration [148], although the site(s) of modification have not been
identified. Notably, an 8-fold increase in MDA-modified GFAP has also
been reported in brain samples from AD patients compared to aged-
matched controls [149], whereas non-significant differences were
found for vimentin modification in this study. Nevertheless, it should be
taken into account that many of these reports use whole tissue samples
for the proteomic studies. Although the evidence for lipoxidation is
solid, novel approaches able to assess oxidative damage in specific re-
gions and/or cell types or subpopulations in the brain may shed valu-
able information on pathogenic mechanisms [150]. Using cellular
models such as fibroblasts and astrocytes, we have recently identified
GFAP as a target for modification by cyPG [80,90]. In astrocytoma
cells, cyPG produced an intense disruption of the GFAP network with
retraction of filaments from the cell periphery and formation of curly
bundles or aggregates in the proximity of the nucleus, whereas in
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mouse primary astrocytes the most obvious effect was filament retrac-
tion and perinuclear condensation [90]. Biotinylated analogs of cyPG
bind to GFAP in a manner dependent on the presence of its single cy-
steine, C294. Moreover, a cysteine deficient GFAP mutant, although
showing altered filament assembly per se, is protected against network
disruption induced by these electrophilic lipids. Similarly, treatment of
cells in the presence of DTT attenuated network disruption, pointing to
the importance of thiol modification in cyPG effect [90].
Protein carbonyl formation. Most of the evidence on protein
carbonyl formation on GFAP has been obtained through the use of
derivatization techniques combined with immunological detection after
immunoprecipitation or 2D analysis, or by using adduct-specific anti-
bodies (reviewed in Ref. [151]). These approaches have demonstrated
PCF in AD, tautopathies including progressive supranuclear palsy and
Pick's disease, and in Huntington disease [146,151–153]. An 8-fold
increase in GFAP protein carbonyl levels has been found in samples
from the frontal cortex of Down's syndrome patients compared to
controls [154]. Moreover GFAP has been identified as the major car-
bonyl containing protein in the cerebral cortex of a patient with acer-
uloplasminemia, the hallmark of which is intracellular iron overload
[155]. From all this evidence, it seems clear that GFAP constitutes a
highly susceptible target for oxidative modifications in various neuro-
degenerative diseases. Nevertheless, whether the modifications lead to
significant network rearrangements and whether they represent a toxic
or a defense mechanism requires further study.
Nitration. Nitrated GFAP has been identified in normal rat cortex
[156,157], and marked increases in nitration have been observed in a
model of hypobaric hypoxia and reoxygenation [157]. In this model,
intense nitration of other cytoskeletal components, including tubulin
and γ-actin has been observed, for which a cooperation of these pro-
teins in cytoskeletal disruption has been proposed.
Although in this review we have not considered the modifications of
GFAP isoforms, the study of their specific modifications could yield
valuable pathogenic information. Indeed, in proteomic studies, up to 46
forms of soluble GFAP could be separated by 2D immunoblotting from
control and AD brain samples, which differed in size, phosphorylation,
glycosylation and oxidation state [158].
4. Desmin and peripherin
Desmin is the main IF protein of mature striated muscle, where it is
located in the sarcolemma, Z-lines, neuromuscular and myotendinous
junctions. This protein provides strength to the muscle fiber during
contraction and facilitates mechanochemical signaling [15,159].
Desmin and its protein binding targets form a scaffold that links the
contractile system to the nucleus, mitochondria and other organelles
through the Z-discs, allowing their crosstalk. This interconnecting role
also enables transport between the extracellular and nuclear matrix
[15,159]. More than 70 mutations in the desmin gene (DES) have been
identified, which lead to different types of myopathy (e.g. myotilino-
pathies and desminopathies), including cardiomyopathy or isolated
myopathies. Mutations have been identified in all the protein domains.
Skeletal and cardiac muscle phenotypes involve mainly mutations af-
fecting rod 2B, abnormal phosphorylation levels, and some oxidative
modifications that correlate with desmin related myopathies (DRMs)
and cardiac disease [15,159].
Desmin is a target for a variety of PTMs including phosphorylation,
ADP-ribosylation, ubiquitination, glycation, oxidation and nitration.
Most of them cause disassembly of the desmin network [160]. Also in
this case, phosphorylation is by far the most studied PTM. Although
alterations in desmin levels or distribution have been frequently en-
countered in pathophysiological situations associated with oxidative
stress or in cellular models of electrophilic stress [161], the precise
characterization of oxidative modifications and their impact on the
function of the protein is not always available. Indeed, muscle activity
induces thermal, mechanical and redox stress, which in cellular models
of desminopathies elicit aggregation of desmin mutants [162] that can
be attenuated by treatment with antioxidants, like, N-acetyl-cysteine or
tocopherol [163].
As described above, oxidative crosslinking-induced dimers of
desmin or of desmin and vimentin have been generated in vitro and
showed impaired assembly [85]. Moreover, purified desmin subjected
to in vitro oxidation with H2O2 and Fe2+ increases its content of
random coil and β-sheet, in turn, decreasing its α-helix content ac-
cording to far-UV CD spectra [164]. Also, oxidation can alter its sus-
ceptibility to proteolytic cleavage [164]. In myocytes, several redox
modifications of desmin have been reported including disulfide linked
and sulfenylated forms of the protein, as has been identified in studies
using diamide, dimedone analogs or peroxide [165,166]. Desmin oxi-
dation has also been confirmed in muscle biopsies from patients with
desminopathies or myotilinopathies [159].
Desmin is also a target for lipoxidation. Functional derangement by
HNE treatment has been reported [161], and acrolein-modified desmin
has been identified in myocytes exposed to this toxic agent [167].
Among other modifications, desmin has also been identified as a
target for nitration [127,159], and increased formation of protein car-
bonyls in skeletal muscle has been detected in sepsis, ischemia-re-
perfusion, diabetes and chronic obstructive pulmonary disease (re-
viewed in Ref. [168]). However, the functional consequences of these
modifications are not yet clear.
Peripherin expression is mainly restricted to the peripheral nervous
system, but also occurs in neurons of the CNS. There are several forms
of peripherin generated by alternative splicing, some of which increase
in response to traumatic neuronal injury [169]. The role of this protein
is unclear, but it seems to contribute to IF cytoskeleton organization
and axonal elongation. The protein is a major autoantigen in type 1
diabetes [170] and appears in compact inclusions in several diseases,
including amyotrophic lateral sclerosis (ALS). Screening for sequence
variants in the peripherin gene (PRPH) has been performed in patients
with ALS and several SNPs have been identified [171]. These include an
insertion in intron 8 (IVS8-36insA), a 1 bp deletion in exon 1 (228delC)
leading to a truncated form of the protein, and a homozygous mutation
in the first linker generating the D141Y mutation. Peripherin over-
expression induces motor neuron degeneration in transgenic mice,
whereas the knockout mice seem to compensate lack of PRPH expres-
sion by inducing that of vimentin and α-internexin, apparently leading
to decreased myelination of only a subset of sensory fibers [172].
Peripherin is by far the less studied of the type III IF class, and is the
only one that possesses two cysteine residues. Nevertheless, several
oxidative modifications have been reported. A disulfide-linked periph-
erin dimer of 130 kDa has been detected in rat sciatic nerve and dorsal
root ganglia [173]. Non-differentiated N2a neuroblastoma cells treated
with hydrogen peroxide showed concentration-dependent changes in
the levels of peripherin, together with alterations in the proportion of
the peripherin forms, Per-58 and Per-45. Moreover, peroxide
(100–500 μM) induced loss of filament structure and inclusions in non-
differentiated cells, whereas retraction of neurites was detected at
10 μM. However, peripherin filaments and aggregates did not colocalize
with carbonyl markers, despite increased total protein carbonyl for-
mation [174].
The best characterized oxidative modification of peripherin is ni-
tration, which has been described upon NGF-induced differentiation in
PC12 cells, and occurs at the head (Y17) and tail (Y376) domains [175].
Apparently, the ratio between nitration levels and peripherin expres-
sion before and after NGF addition increases during differentiation.
Remarkably, nitrated peripherin is only present in the insoluble cytos-
keletal fraction. Heavy tyrosine nitration and phosphorylation of per-
ipherin have been observed in ALS, in association with disruption of
filament association and appearance of inclusions or aggregates [169].
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5. Interplay between PTMs in type III IFs
In any given situation, proteins are subjected to multiple PTMs that
can occur on the same or on different protein molecules in different
combinations, giving rise to structurally and functionally different
proteoforms. Type III IFs and, in particular, their conserved cysteine
residues, are emerging as hot spots for modification by oxidants and
electrophiles. Indeed, the studies summarized above highlight the sus-
ceptibility of these cysteine residues to a plethora of modifications in-
cluding nitrosation, disulfide formation, sulfenylation and addition of
various electrophilic lipids including HNE, MDA and cyPG.
Interestingly, a complex interplay between modifications can take place
both by direct and indirect mechanisms (Fig. 5). Reversible cysteine
modifications, for instance, glutathionylation, could prevent irrever-
sible oxidations or adduct formation; however, some oxidative mod-
ifications can increase or decrease the reactivity of the affected residues
[176].
Phosphorylation is probably the most studied modification reg-
ulating protein function. Many oxidant species act on signaling pro-
teins, for instance, kinases and phosphatases, triggering additional
modifications of IFs. Vimentin is a target for phosphorylation by
numerous kinases, including PKA and AKT, which are directly and/or
indirectly regulated by redox mechanisms [177]. The impact of oxi-
dative modifications on kinase activity can lead to activation or in-
hibition. In turn, tyrosine phosphatases are generally inhibited by oxi-
dative stress, whereas oxidation of serine/threonine protein
phosphatases can result in activation or inhibition. Interplay of nitric
oxide with vimentin phosphorylation has been reported through mod-
ulation of PP2A activity [178]. Phosphatase inhibition would result in
vimentin hyperphosphorylation, which could contribute to network
disruption by oxidative modifications. In this context, we have recently
observed that the phosphatase inhibitor calyculin A, an inhibitor of
PP2A and PP1 phosphatases, potentiated the fragmentation of vimentin
network induced by diamide, whereas a phosphorylation-deficient vi-
mentin mutant “SA mutant”, in which 11 phoshorylatable residues of
the N-terminal domain had been substituted by alanines, was partially
protected from the diamide-disruptive effect [91].
A complex interplay can also occur with the protein degradation
machinery. Certain oxidative insults or other types of stress can lead to
the degradation of vimentin and GFAP by activating proteases [179],
although some ubiquitin ligases and subunits of the proteasome can be
inhibited by lipoxidation [180], which, as stated above, would result in
Fig. 5. Interplay between posttranslational modifications in type III intermediate filaments. Under oxidative stress, several oxidants are generated that can
react with unsaturated lipids in membranes giving rise to the formation of electrophilic lipid species. These can directly form adducts with proteins in a process called
lipoxidation. Oxidative stress also diminishes the ratio GSH/GSSG and favors the formation of disulfide bonds between glutathione and thiol groups in proteins
(glutathionylation). This modification can also be mediated by nitrosoglutathione, which can also induce S-nitrosation. Oxidative modifications of cysteine residues
can also lead to the formation of sulfenic, sulfinic and sulfonic acids. Other oxidative modifications include protein carbonyl formation, nitration or formation of
protein crosslinks (see Ref. [41] for review). Other PTMs that are under redox control, such as phosphorylation and protein degradation will be modulated in
situations of oxidative stress, thus contributing to the diversity and complexity of proteoforms arising under these conditions. The function of type III IFs will be also
affected by oxidative modifications of interacting proteins, such as those described for plectin, actin, and several chaperones. Importantly, interplay can also take
place with other PTMs, including those listed in the lower panel, which can occur on the same or nearby residues, affecting their availability or accessibility to
modification.
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accumulation of damaged proteins.
Interestingly, due to their polyelectrolyte properties, IFs interact
with cations such as Ca2+, Mg2+ or Zn2+ which, depending on their
size and concentration, influence IF assembly [13,92,181]. Importantly,
Zn2+ availability can influence the occurrence of certain PTMs on vi-
mentin [13], which could occur through direct interaction or through
its capacity to elicit antioxidant or pro-oxidant effects [182,183]. Al-
though Zn2+ is a redox-inert ion, it can influence cellular redox status
because it is necessary for the activity of enzymes involved in the an-
tioxidant defense, whereas its deficiency or excess cause oxidative stress
[183].
In addition, modification of interacting proteins can have an im-
portant impact on the regulation of IFs localization and function. The
linker protein plectin has been reported to be nitrosated, affecting vi-
mentin distribution [184], whereas actin and tubulin are targets for
various oxidative and lipoxidative modifications [56]. Moreover, cer-
tain modifications can compete for the same site, for instance, carba-
moylation, resulting from modification by isocyanic acid [185], can
occur at citrullination sites, and tyrosine nitration could preclude
phosphorylation. Modification of a given residue can also affect that of
nearby amino acids, either by altering their reactivity or their accessi-
bility. Therefore, bulky moieties can shield nearby residues, but certain
modifications can cause unfolding and exposure of additional amino
acids for modification. Additionally, many conditions associated with
oxidative stress and oxidative modifications trigger important changes
in gene expression, including the antioxidant stress response [57],
contributing to the complexity of the effects.
6. Vimentin and other IFs as drug targets
Given their implication in pathological processes, IFs in general, and
those belonging to the type III family in particular, are becoming im-
portant drug targets. Indeed, hypothesis-driven, as well as virtual and
pharmacological screening approaches are being used to find small
molecule modulators of these proteins. High expression levels of type III
IF proteins have been considered as pathogenic factors in several dis-
eases. Therefore, efforts have been devoted to find strategies to mod-
ulate their levels or organization in cells [186,187]. Nevertheless, this
section will focus on approaches related to PTMs and more precisely on
drugs that directly bind to these proteins and preferentially interact
with their conserved cysteine residue.
As vimentin C328 and the equivalent cysteine residues in the other
members of the family seem to be highly susceptible to modification by
oxidant and electrophilic species, their modification by cysteine-re-
active drugs is worth exploring. Among the first compounds reported to
target vimentin C328 is the withanolide natural product withaferin A
(WFA). This molecule was studied based on its antitumor and anti-
angiogenic properties and was reported to covalently bind to C328 and
induce vimentin aggregation in vitro and filament disruption in cells
[188]. In addition, WFA caused vimentin downregulation in cells and
showed in vivo antiangiogenic effects, reportedly mediated by vimentin
[188]. It was later described that this molecule could bind to the single
GFAP cysteine residue, C294 [189]. Moreover, it was shown that WFA
reduced the levels of both vimentin and GFAP in primary astrocytes as
well as in mouse retina in vivo [189]. Therefore, these WFA actions
could be beneficial in situations associated with increased expression of
these proteins, such as reactive gliosis. Thus, WFA has become a pop-
ular tool employed to target and disrupt the vimentin network in sev-
eral experimental models [190]. However, being a cysteine reactive
molecule, WFA could interact with other cellular targets. In fact, several
works have called attention to its lack of specificity [191]. Indeed, WFA
has recently been reported to covalently bind the heterogeneous nu-
clear ribonucleoprotein K (hnRNP-K) [192], and tubulin, and induce
the degradation of the latter [193]. Moreover a vimentin mutant
lacking C328 appears to respond to WFA as well [191]. Recent mole-
cular dynamics simulations indicate that WFA binds in the vicinity of
C328, but not directly to this residue [192]. Therefore, although WFA
may be useful to disrupt vimentin and other type III IF proteins, its use
as a selective target should be performed cautiously. Interestingly, the
compound arylquin 1 also binds to vimentin at a region close to the
cysteine residue. In this case, interaction of arylquins with vimentin
displaced the binding of Par4, an apoptosis-inducing protein, with
consequences for cell viability [194].
Additional evidence of the importance of C328 as a drug target has
risen from the garlic compound ajoene [195], which has been shown to
form a disulfide bond with this residue. This modification is associated
with condensation of vimentin filaments and with an impairment of
several vimentin-related processes, including cell migration and inva-
sion of cancer cells. These effects were attenuated in cells in which
vimentin expression had been transiently knocked down, thus pointing
to vimentin importance as mediator of ajoene actions. Notably, another
garlic defense substance, allicin, has been shown to induce S-thioally-
lation of several cytoskeletal proteins, including vimentin, in Jurkat
cells [196]. In addition, phenyl vinyl sulfones, mechanism-based in-
hibitors of protein tyrosine phosphatase, covalently bind vimentin C328
in cells, although the significance of this finding is still not known
[197,198].
A number of proteomic studies searching for protein targets of drugs
or natural products have found vimentin [199], although the precise
site of interaction or the functional consequences have not always been
elucidated. Additional compounds found to bind vimentin include two
quinone methide metabolites of the phenolic antioxidant butylated
hydroxytoluene. These metabolites are believed to be responsible for
promoting lung tumor formation in mice [200]. In contrast, the green
tea polyphenol epigallocatechin gallate binds to vimentin and inhibits
its phosphorylation in cells, which is associated with an anti-
proliferative effect [201].
7. Concluding remarks
Type III IF proteins are arising as integrators of basic cellular pro-
cesses and as sensors of stress. These proteins, and in particular their
conserved cysteine residue, have been proposed as hot spots for PTMs.
Modification of this cysteine residue leads to marked reorganization of
type III IFs in cells, which is supported by the lack of response of cy-
steine-deficient mutants. Remarkably, the nature of the reorganization
appears to depend on the extent and the structure of the modification,
illustrating an exceptional versatility of type III IFs remodeling.
Moreover, this suggests that the conserved cysteine residue of type III
IFs functions as a hub that can accept different types of modifying
moieties and transduces them into distinct cytoskeletal responses, ei-
ther per se or in cooperation with other PTMs, thus acting as a sensor
for various signals. The position of the conserved cysteine residue in the
structure of the protein could be critical for the functional outcome of
the modifications, affecting its organization in filaments. Nevertheless,
many aspects of structure and function of type III IFs still need in-
vestigation. Elucidation of the structure of filaments and of their var-
ious arrangements in cells will be key to understand the basis of their
response to stress. Moreover, the downstream consequences of the di-
verse reorganizations are still poorly understood. The modification of
type III IFs by oxidant and electrophilic species could impact on many
cellular processes, but it also could represent a defensive mechanism by
which these proteins would act as decoys or scavengers of reactive
species. Therefore, further identification and characterization of the
PTMs occurring in vivo, both structurally and quantitatively, will be
necessary to elucidate their role in physiological IF regulation and their
potentially protective or pathogenic effects under pathophysiological
conditions. Finally, certain oxidative PTMs of type III IFs can be con-
sidered as disease biomarkers, whereas their modulation could become
a therapeutic strategy in a variety of illnesses.
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